与T2DM患者的血糖控制相关的因素:来自中国的一项横截面研究的证据
Wenting Luo1, Jiayu Zhang2, Yanxing Luo3
1Department of Scientific Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, No.24, Bailu Road, Siming District, Xiamen, 361003, Fujian, China.
BMC endocrine disorders
|June 3, 2024
概括
胰岛素治疗和定期诊所访问对2型糖尿病 (T2DM) 患者的血糖控制有显著影响. 这些因素是有效管理糖化血红蛋白水平的关键.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 临床研究 临床研究
背景情况:
- 2型糖尿病 (T2DM) 是一个重大的全球健康挑战.
- 有效的血糖控制对于预防T2DM并发症至关重要.
- 确定影响血糖控制的因素对于优化患者的治疗结果至关重要.
研究的目的:
- 调查与诊断为T2DM的患者的血糖控制相关的关键因素.
- 分析各种患者特征和治疗方式对糖化血红蛋白 (HbA1c) 水平的独立影响.
主要方法:
- 一项涉及305名T2DM患者的横截面研究设计.
- 数据收集包括人口统计,生活方式和治疗信息.
- 使用单变量和多变量逻辑回归 (SPSS 26.0) 的统计分析.
主要成果:
- 胰岛素治疗与改善的血糖控制有关 (OR = 2.233,P = 0.026).
- 定期的诊所访问独立地与更好的血糖控制有关 (OR = 0.567,P = 0.040).
- 在胰岛素治疗和诊所访问频率之间没有发现显著的相互作用.
结论:
- 过去或当前的胰岛素治疗和一致的临床预约出席是T2DM中糖化血红蛋白控制的显著预测因素.
- 对T2DM患者建议采用包含这些因素的个性化管理策略.
- 进一步的研究可以探索这些关联背后的机制.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
523
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
523
Diabetes: Management and Pharmacotherapy
260
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
260
Carbohydrate Metabolism
11.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173


